Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells

SIMPLE SUMMARY: GSK2879552 is a LSD1 inhibitor in clinical development. By structural modification, we obtained an analogue that is a potent and selective dual inhibitor of HDAC6 and LSD1 (IC(50) 110 and 540 nM, respectively). The dual targeting agent was superior to GSK2879552 in the growth inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulut, Ipek, Lee, Adam, Cevatemre, Buse, Ruzic, Dusan, Belle, Roman, Kawamura, Akane, Gul, Sheraz, Nikolic, Katarina, Ganesan, A., Acilan, Ceyda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737972/
https://www.ncbi.nlm.nih.gov/pubmed/36497494
http://dx.doi.org/10.3390/cancers14236014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737972/
https://www.ncbi.nlm.nih.gov/pubmed/36497494
http://dx.doi.org/10.3390/cancers14236014

Ejemplares similares